Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NCT02230891Phase 2
Key facts
Phase 2, randomised, open-label trial of carvedilol and spironolactone in heart failure (HF), sponsored by VA Office of Research & Development. Started Oct 2014; status: completed.
Veterans aged >40 with Stage A/B heart failure, elevated hs-cTnT (>5 ng/L), and 10-year HF risk >5%.
Despite advances in cardiovascular care, the occurrence of heart failure (HF) is steadily increasing. The increase in HF rates poses enormous challenges, as once an individual becomes symptomatic or requires hospitalization with HF, the prognosis remains poor. Therefore, prevention of HF is essential. HF prevention is a critical issue as HF risk factors that include common medical conditions such as hypertension and diabetes are also increasing. However, not everyone with these risk factors develops HF. Using novel blood tests, the investigators propose to identify and treat subjects at…
Beyond the preview
Full results, competitive context and analysis are in the Gosset platform.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on NCT02230891.